EUCTR2007-000491-16-DE进行中（未招募）不适用
A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1ß monoclonal antibody) in patients with active rheumatoid arthritis - not available
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who completed the core CACZ885A2201 study may enter the extension study upon signing informed consent. A patient is defined as completing the study if he/she completed the core CACZ885A2201 study up to and including Visit 12.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients for whom continued treatment in the extension is not considered appropriate by the treating physician.
- •Patients who were non-compliant or who demonstrated a major protocol violation in the core CACZ885A2201 study.
- •Patients who discontinued from the core CACZ885A2201 study before Visit 12.
研究者
相似试验
进行中（未招募）
不适用
A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1ß monoclonal antibody) in patients with active rheumatoid arthritis - not availableMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-000491-16-BEovartis Pharma Services AG
进行中（未招募）
不适用
A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1ß monoclonal antibody) in patients with active rheumatoid arthritis - not availableMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-000491-16-ATovartis Pharma Services AG260
进行中（未招募）
不适用
A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorderEUCTR2004-000687-27-ATovartis Pharma AG215
进行中（未招募）
不适用
A 52-week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2000 mg/d in the treatment of manic episodes of bipolar I disorderBipolar I disorder, manic and mixed episodesEUCTR2004-000686-35-FIovartis Pharma AG215
进行中（未招募）
不适用
A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’sdisease - A2202E1EUCTR2009-011621-14-ATovartis Pharma Services AG72